🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Alignment Healthcare, Inc. ALHC R2KR3KPHARMA

Healthcare · Healthcare Plans · United States
https://www.alignmenthealth.com
Company Profile ↓
$8.06
-45.39% 1Y
Mkt Cap$1.67B
P/E42.42
P/B5.89
52W High$24.56
52W Low$7.54
Book Value$1.28
EPS (TTM)$0.19

Company Overview

Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States. It delivers customized healthcare experience to meet the needs of seniors through its Medicare Advantage plans. Alignment Healthcare, Inc. was founded in 2013 and is based in Orange, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 20.0%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 31.8% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $3.95B (+46.1% YoY); net profit $-724.00K.
  • Trailing 12 Months Year-on-year growth — revenue +31.6%, earnings +142.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 31.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:31.78%
1 Year:31.60%

Compounded Profit Growth

5 Years:-
1 Year:142.90%

Stock Price Performance

1 Year:-45.39%
6 Months:-61.86%
3 Months:-56.83%
1 Month:+5.08%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 3% of range
$7.54 $24.56
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)37.72 · Neutral
Price Performance
1M+5.08%
3M-56.83%
6M-61.86%
1Y-45.39%
Valuation vs Sector

P/E of 42.42 is above the sector median of 25.45 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 20.0%.
  • Compounding revenue at 31.8% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 67.2% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
42.42
Industry PE
25.45
Forward P/E
10.97
PEG Ratio
-
Book Value
$1.28
Price to Book
5.89
P/S
0.34
EV/EBITDA
16.04
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
31.78%
Profit 5Y
-
Revenue (YoY)
31.60%
Earnings (YoY)
142.90%

Profitability & Returns

ROCE
2.90%
ROE
20.04%
ROA
3.07%
Profit Margin
0.89%
Op Margin
3.15%
Gross Margin
12.55%
EPS (Latest Qtr)
$0.17
EPS (TTM)
$0.19

Balance Sheet & Liquidity

Debt/Equity
1.25
Quick Ratio
1.46
Current Ratio
1.70
Debt
$330.50M
Total Assets
$1.28B
Current Assets
$1.16B
Working Capital
$394.71M

Ownership

Promoter Holding
2.57%
Chg in Prom Hold
-0.01%
FII / Inst Holding
116.00%
Chg in FII Hold
0.03%

Financial Snapshot

Enterprise Value
$1.67B
Total Revenue (TTM)
$4.58B
EBITDA
$87.42M
Free Cash Flow
$188.58M
Operating Cash Flow
$205.55M
Shares Outstanding
207.44M
Gross Margin
12.55%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ALHC Alignment Healthcare, Inc. R2KR3KPHARMA 8.06 42.42 $1.67B 0.00% 2.90% 20.04% 31.78% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,273.46 42.83 $1.14T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 263.81 30.60 $635.76B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.64 80.69 $504.76B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 418.09 26.85 $375.28B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 145.27 116.22 $358.41B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 151.12 22.83 $287.24B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 171.49 25.63 $265.96B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 673.82 36.30 $249.14B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 224.27M243.96M245.49M267.00M308.74M293.27M345.29M366.18M359.98M434.81M456.88M450.24M----926.93M1.02B993.70M1.01B1.24B-
Cost of Revenue ----------------820.90M881.74M868.02M889.49M1.09B-
Gross Profit ----------------106.03M133.55M125.67M123.31M144.48M-
Operating Expenses ----------------111.42M110.80M117.99M133.59M128.98M-
Operating Income -5.12M12.59M15.06M-52.66M-40.49M-41.45M-36.48M-6.65M-33.41M-32.49M-23.66M-29.76M-41.11M-18.38M---5.39M22.75M7.68M-10.28M15.50M42.10M
EBITDA ----------------2.24M29.86M15.67M-2.45M23.36M-
Interest Expense ----------------3.95M3.95M3.95M3.95M4.06M-
Pretax Income -----------------9.33M18.88M3.73M-14.23M11.44M-
Tax Provision ----------------21.00K3.22M2.00K-3.23M25.00K-
Net Income -10.07M8.37M10.85M-56.87M-44.76M-45.82M-40.82M-11.58M-40.25M-37.28M-28.48M-35.05M-46.52M-24.01M---9.11M15.67M3.73M-11.01M11.42M36.56M
Diluted EPS -----0.25-0.26-0.23-0.06-0.22-0.20-0.15-0.19-0.25-0.13---0.050.070.02-0.050.050.17

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 753.97M955.39M1.17B1.43B1.82B2.70B3.95B
Cost of Revenue ---1.25B1.62B2.41B3.46B
Gross Profit ---184.28M201.03M296.69M488.56M
Operating Expenses ---312.92M328.85M398.25M473.81M
Operating Income -29.48M-5.26M-178.07M-128.64M-127.82M-101.56M14.75M
EBITDA ----113.53M-105.30M-77.44M45.32M
Interest Expense ---18.29M21.23M23.55M15.80M
Pretax Income ----149.30M-148.19M-128.05M-958.00K
Tax Provision ---339.00K-22.00K21.00K20.00K
Net Income -44.73M-22.93M-195.29M-149.55M-148.02M-128.03M-724.00K
Diluted EPS --0.15-1.14-0.83-0.79-0.670.00

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --338.50M-633.86M591.88M782.06M1.07B
Current Assets ----544.55M483.54M661.64M951.58M
Cash & Equivalents -86.48M207.31M-409.55M202.90M432.86M575.82M
Inventory --------
Receivables ----92.89M119.75M153.90M253.21M
Total Liabilities --307.89M-394.56M433.81M681.11M886.51M
Current Liabilities --153.45M-229.96M263.02M351.85M556.87M
Long Term Debt --144.17M-160.90M161.81M321.43M323.18M
Total Debt ----164.60M170.79M329.26M329.64M
Total Equity -33.66M-78.71M30.61M-238.13M156.95M99.85M179.28M
Shares Outstanding ----187.28M188.95M191.78M204.15M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 9.21M7.56M--45.43M-59.19M34.77M139.93M
Investing Cash Flow -10.24M-16.36M--28.22M-147.26M39.19M-14.97M
Financing Cash Flow 52.66M130.12M-16.59M105.00K156.03M18.04M
Capital Expenditure ----23.77M-35.99M-41.42M-26.78M
Free Cash Flow ----69.20M-95.18M-6.65M113.15M
Net Change in Cash ----57.05M-206.34M229.99M142.99M

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---12.8%11.0%11.0%12.4%
Operating Margin % -3.9%-0.6%-15.3%-9.0%-7.0%-3.8%0.4%
Net Margin % -5.9%-2.4%-16.7%-10.4%-8.1%-4.7%-0.0%
ROE % 56.8%-74.9%--62.8%-94.3%-128.2%-0.4%
ROCE % --2.8%--31.8%-38.9%-23.6%2.9%

Shareholding Pattern

Insiders
2.57%
Institutions
116.00%
Public Float
119.05%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 9.32% 19.34M $145.94M
2 Wellington Management Group, LLP 9.05% 18.78M $141.70M
3 FMR, LLC 6.71% 13.92M $105.06M
4 T. Rowe Price Investment Management, Inc. 6.32% 13.12M $98.99M
5 Vanguard Portfolio Management LLC 5.63% 11.67M $88.07M
6 Invesco Ltd. 5.00% 10.37M $78.21M
7 Bank of America Corporation 4.51% 9.35M $70.52M
8 Vanguard Capital Management LLC 3.93% 8.14M $61.45M
9 William Blair Investment Management, LLC 3.74% 7.76M $58.56M
10 State Street Corporation 3.52% 7.30M $55.06M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ALHC

Yahoo Finance hu, 22 Oct 2026

Analysts Estimate Alignment Healthcare (ALHC) to Report a Decline in Earnings: What to Look Out for

Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo Finance Mon, 19 Oct 2026

How Investors May Respond To Alignment Healthcare (ALHC) New Medicare Plan

Alignment Healthcare recently announced Central Health Harmony, a culturally tailored HMO Medicare Advantage plan for Chinese, Korean and Vietnamese speaking seniors in Los Angeles and Orange counties, set to begin coverage in 2027 with a b…

Yahoo Finance Wed, 14 Oct 2026

Alignment Healthcare to Announce Third Quarter 2026 Financial Results and Host Conference Call Thursday, Oct. 29, 2026

ORANGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its third quarter 2026 financial results on Thursday, Oct. 29, 2026, after market close. Following the release, the company will host …

Yahoo Finance ue, 13 Oct 2026

Alignment sues CMS over 2027 Medicare Advantage star ratings crash

The lawsuit isn’t a surprise, after Alignment told investors it would take all available actions to improve its quality scores.

Yahoo Finance ue, 13 Oct 2026

Why Alignment Healthcare (ALHC) Stock Is Up Today

Shares of health insurance company Alignment Healthcare (NASDAQ:ALHC) jumped 8.6% in the afternoon session after Alignment Health Plan, its subsidiary, announced that its new Central Health Harmony Medicare Advantage plan will be available …

Yahoo Finance Fri, 09 Oct 2026

Why Alignment Healthcare (ALHC) Shares Are Trading Lower Today

Shares of health insurance company Alignment Healthcare (NASDAQ:ALHC) fell 19.2% in the pre-market session after William Blair downgraded the company to Market Perform from Outperform following a regulatory filing detailing lower quality ra…

ALHC — Frequently Asked Questions

What is the current share price of Alignment Healthcare, Inc. (ALHC)?

As of 2026-10-23 16:27 PDT, Alignment Healthcare, Inc. (ALHC) trades at $8.06 on NasdaqGS. Its 52-week range is $7.54 to $24.56.

What is the market capitalisation of ALHC?

Alignment Healthcare, Inc. (ALHC) has a market capitalisation of $1.67B on NasdaqGS.

What is the P/E ratio of ALHC?

ALHC trades at a trailing price-to-earnings (P/E) ratio of 42.42. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 5.89.

What is the return on equity (ROE) of ALHC?

ALHC has a return on equity (ROE) of 20.04%. Its return on capital employed (ROCE) is 2.90%.

Is ALHC a good stock to buy?

This page provides a data-driven analysis of Alignment Healthcare, Inc. (ALHC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space